-
This study was designed to determine whether intensive glucose control in ICU patients reduces mortality at 90 days. Secondary outcomes included survival time during the 90 days, cause-specific death, duration of mechanical ventilation, need for renal replacement therapy, and hospital and ICU lengths of stay.
-
Intensive insulin therapy in the ICU is a dynamic and controversial issue that has played out in the medical literature, at the bedside, and in the offices of policy makers over the last 8 years.
-
This study examined patients' bath basins as a possible reservoir for bacterial colonization and a risk factor for subsequent hospital-acquired infections.
-
In this issue: NSAIDs in the elderly; managing GI and CVD risk with NSAIDs; low-dose naltrexone and fibromyalgia; treating glucocorticoid-induced bone loss; FDA Actions.
-
-
-
Once-a-week rosuvastatin therapy was well tolerated in patients with a history of adverse events to one or more statins and led to significantly improved lipoprotein changes.
-
We don't have the slightest idea whether evidence of gallbladder dyskinesia should warrant cholecystectomy or not.
-
Almost one-fifth of Medicare patients who were discharged from a hospital were rehospitalized within 30 days, and about a third were rehospitalized within 90 days. Most of these readmissions were not planned.
-
Everolimus is the newest oral kinase inhibitor approved for the treatment of advanced renal cell carcinoma.
